IMDX
Insight Molecular Diagnostics Inc.
There isn't enough reported data to score IMDX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IMDX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
IMDX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IMDX PE Valuation
IMDX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IMDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IMDX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IMDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$2.21 |
| Q1 2026 | -$1.51 | +$2.28 |
| Q4 2025 | -$1.65 | +$3.01 |
| Q3 2025 | -$3.09 | +$1.27 |
| Q2 2025 | -$3.73 | +$0.46 |
| Q1 2025 | -$3.79 | +$1.11 |
| Q4 2024 | -$4.66 | -$1.29 |
| Q3 2024 | -$4.36 | +$4.76 |
IMDX is still losing money, but far less than before: $1.52 per share over the past year, against $15.60 at its worst in early 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IMDX on earnings quality, reporting a profit while its opponent remains loss making.
IMDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $239K | -54% |
| Q1 2026 | $32K | -99% |
| Q4 2025 | $1.1M | -23% |
| Q3 2025 | $260K | +126% |
| Q2 2025 | $518K | +398% |
| Q1 2025 | $2.1M | +1115% |
| Q4 2024 | $1.5M | +373% |
| Q3 2024 | $115K | -73% |
IMDX's revenue has slid since its 2021 peak: $239,000 last quarter, down 54% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4771% | -2871 points |
| Q1 2026 | -13791% | -13473 points |
| Q4 2025 | -2058% | +205 points |
| Q3 2025 | -4249% | +7503 points |
| Q2 2025 | -1900% | +2554 points |
| Q1 2025 | -318% | +4947 points |
| Q4 2024 | -2263% | +2890 points |
| Q3 2024 | -11752% | -10234 points |
IMDX's operating margin was −4771% last quarter, down 2871 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IMDX on profitability, with a higher operating margin.
IMDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10M | -$3.4M |
| Q1 2026 | -$8.3M | -$2.1M |
| Q4 2025 | -$7M | -$1.5M |
| Q3 2025 | -$5.6M | +$86K |
| Q2 2025 | -$6.6M | -$459K |
| Q1 2025 | -$6.2M | -$2.3M |
| Q4 2024 | -$5.6M | -$742K |
| Q4 2023 | -$4.8M | +$5.6M |
IMDX has burned cash in almost every quarter: −$31M over the past year, against −$24M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IMDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.5% | +2.2M shares |
| 1 year | +15% | +4.7M shares |
| 3 years | +520% | +30.8M shares |
IMDX has 37M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IMDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IMDX Net Leverage
IMDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IMDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.9 | Oversold |
| Stochastic | 5.8 | Oversold |
IMDX's weekly RSI is 28 (oversold) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IMDX PE vs Healthcare Sector
IMDX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IMDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 24% below |
| 20 week MA | $3.96 | 42% below |
| 50 week MA | $4.85 | 52% below |
| 100 week MA | $4.09 | 44% below |
| 200 week MA | $3.95 | 42% below |
IMDX is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IMDX on trend strength, trading above more of its moving averages.
IMDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $42.4 | $47.0 | +11% |
| 2021 | $47.0 | $46.0 | -2.1% |
| 2022 | $46.0 | $7.60 | -83% |
| 2023 | $7.60 | $2.50 | -67% |
| 2024 | $2.50 | $2.11 | -16% |
| 2025 | $2.11 | $6.37 | +202% |
| 2026 YTD | $6.37 | $2.31 | -64% |
IMDX's yearly returns have swung widely, from +202% in 2025 to −83% in 2022. It's down 64% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IMDX on returns for 2026, with the stronger performance.